Salt Composition
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Used In
Cancer of colon and rectum
Customers also bought
More About Jupiplatin 50 Injection
Benefits
In Cancer of colon and rectum : Cancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer from two parts of the large intestine, namely, the colon or rectum. In this type of cancer, the person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss, and fatigue. Jupiplatin 50 Injection treats and also lowers the risk of developing further cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.
Side Effects
Side effects of Jupiplatin Injection The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you�re worried about them Common side effects of Jupiplatin Nausea Fatigue Anemia (low number of red blood cells)Vomiting Diarrhea Decreased white blood cell count (neutrophils)Low blood platelets Increased liver enzymes Peripheral neuropathy (tingling and numbness of feet and hand)Stomatitis (Inflammation of the mouth)
How to use
How to use Jupiplatin Injection Your doctor or nurse will give you this medicine. Kindly do not self administer.
How it works
How Jupiplatin Injection works Jupiplatin 50 Injection is an anti-cancer medication. It works by damaging the genetic material (DNA and RNA) of the cancer cells which stops their growth and multiplication.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Jupiplatin 50 Injection . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Jupiplatin 50 Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Doctor consultation is advised.
Jupiplatin 50 Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Jupiplatin 50 Injection may cause side effects which could affect your ability to drive.Oxaliplatin_name$ treatment may result in an increased risk of dizziness, nausea, and vomiting, and other neurological symptoms that affect walking and this may affect your ability to drive.
Jupiplatin 50 Injection should be used with caution in patients with severe kidney disease. Dose adjustment of Jupiplatin 50 Injection may be needed. Doctor consultation is advised.Limited information is available on the use of Jupiplatin 50 Injection in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
Jupiplatin 50 Injection should be used with caution in patients with liver disease. Dose adjustment of Jupiplatin 50 Injection may be needed. Doctor consultation is advised.
What if I forget to take it?
If a dose of Jupiplatin 50 Injection is missed, it's advisable to consult your doctor.
References
Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1689-90
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 944
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1034-35
Oxaliplatin. Hayes, UK: Ranbaxy (UK) Limited a Sun Pharmaceutical Company; 2011 (22 Jan. 2019)
Oxaliplatin. Bridgewater, New Jersey: sanofi-aventis U.S; 2002 (26 Mar. 2019)
Central Drugs Standard Control Organisation (CDSCO) (26 Mar. 2019)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
